1. The Risk of Exacerbation of Myasthenia Gravis After COVID‐19 Omicron Infection
- Author
-
Nana Zhang, Ziya Wang, Dongren Sun, Hongxi Chen, and Hongyu Zhou
- Subjects
COVID‐19 ,myasthenia gravis ,Omicron ,Neurosciences. Biological psychiatry. Neuropsychiatry ,RC321-571 - Abstract
ABSTRACT Objective The aim of this study is to ascertain whether COVID‐19 Omicron infection is associated with exacerbations in these myasthenia gravis (MG) patients. Result In total, 289 MG patients (comprising 60% females, with an average age of 46 ± 15 years) were enrolled. A total of 80.9% of MG patients reported a COVID‐19 infection, with the majority experiencing a benign course (88%). MG patients who experienced COVID‐19 infection demonstrated a higher likelihood of MG exacerbation, compared to those without the infection (18.8% vs. 7.3%, p = 0.039). In the survival analysis, after adjusting for confounding factors, the hazard ratio (HR) for exacerbation post‐infection was found to be 3.38 (95% CI 1.20–9.53, p = 0.021). Compared to the exacerbation rates observed in JTA21, an increase was noted in DTM23 among COVID‐19‐infected MG patients (4.4% vs. 17.2%, p < 0.001). Conclusion The COVID‐19 is the risk of MG exacerbation.
- Published
- 2024
- Full Text
- View/download PDF